Original Research Article

Frequency of cardiomyopathy in children having Thalassemia major: A cross-sectional study

Abstract

Aim: To determine the frequency of cardiomyopathy in children having Thalassemia major diagnosed on the basis of Echocardiography

Study design: A cross-sectional study

Place and Duration: Paediatric department at Peoples medical college hospital (PMCH), Nawabshah from September 2019 to March 2020

Methodology: A total of 236 Thalessemic children visiting as outpatients or inpatients meeting inclusion criteria were enrolled. Informed consent was taken from the patients or their attendants. All demographic variables that included age, gender, address, educational status, family history, age of diagnosis of the disease, start of treatment and number of transfusions graded as none, occasional, were included. Echocardiography findings were performed and then recorded.

Results: Mean age of the patients was 10.60±4.064 (5-18) years, 110(49.1%) study subjects were female and 126(50.8%) were male patients. While 75(31.78%) study subjects have family history of thalassemia. A total of 87(36.9%) study subjects have left ventricular dysfunction, 13(14.9%) have global dysfunction, 11(12.6%) have isolated systolic dysfunction and 63(72.4%) have isolated diastolic dysfunction.

UNDER PEER REVIEW

Conclusion: In -thalassemia, heart disease is the key determinant of prognosis and survival. In this study we found a significant number of thalassemia children having cardiac involvement and ventricular dysfunction

Key Words: cardiomyopathy, Thalassemia major, Echocardiography, Children, ventricular dysfunction

UNDER PEER REVIEW

Introduction

Thalassemia is an autosomal recessive condition that affects about 15 million people globally [1]. The disease is notably prevalent among Mediterranean and Asian peoples, with the Maldives population having the highest rate of carrier state (18%) [2, 3]. In Pakistan, almost forty thousand children are infected by Thalassemia major, with an additional five thousand added each year. Thalassemia was diagnosed on electrophoresis in 61 percent of Pakistanis in 2013, with thalassemia significant occurring in 5.9% of the population [4].

Cardiomyopathies are cardiac muscle illnesses that cause heart failure, either as a result of a dilated left ventricle and decreased contractility [5]. The cause of cardiomyopathy in Thalassemia major is multifaceted, with iron overload playing a significant role. Despite breakthroughs in treatment, cardiac problems from iron overload remain the leading cause of morbidity and mortality [6]. Diastolic dysfunction precedes systolic dysfunction in Thalessemic cardiomyopathy, and early chelation treatment intervention is critical due to a poor prognosis.

Clinically there is a variable presentation of heart failure including exertional dyspnea, orthopnea and crackles on examination in case of left heart failure and for right heart failure increased jugular venous dilatation, hepatomegaly, peripheral edema, tender liver and ascites. Doppler

echocardiography is the imaging modality of choice for revealing progressive myocardial contractility [7].

According to Faruqi et al, 88.1 percent of Thalessemic patients had echocardiographic abnormalities. Cardiovascular problems include tachy-bradyarrythmia, conduction abnormalities, abrupt cardiac death, and heart failure, according to Faruqi et al in a 2014 research [8]. Another observational study published in 2009 by Arshad et al reported that 38 percent of thalassemic patients' not on chelation therapy or on irregular chelation had LV dysfunction, with systolic dysfunction (2%), diastolic dysfunction (30%), and global dysfunction (3%) cases 9. LV dimensions and stroke volume were also quite large [9].

The current study is planned to determine the frequency of clinical and radiological findings of cardiomyopathy in thalassemia major patients.

In order to help improve the quality of life of patients by regularly assessing cardiac function as poor compliance with chelation, chronic anemia and non-availability of cardiac monitoring is increasing cardiac morbidity in thalassemia major patients.

Methodology

This study was done at Paediatric department at PMCH hospital, Nawabshah from September 2019 to March 2020. Non-probability, convenient sampling technique was used. A sample of 236 patients as calculated by 95% confidence interval and prevalence of global dysfunction in Thalassemia major patients 4% at margin of error 2.5%. All known beta thalassemia major children age between 5-18 years of both gender were included in the study. Thalessemic patients with mental retardation or suffering from some other chronic illness and patients taking oral iron

UNDER PEER REVIEW

chelators were excluded. Hemoglobin electrophoresis was done for the confirmation of beta thalassemia major Hemoglobin F > 60% was labelled as beta thalassemia major.

Data were collected from Thalessemic patients visiting as outpatients or inpatients in Department of Pediatrics in PMCH Hospital meeting inclusion criteria. Consent was taken parents were assured for confidentiality of information. Plain language was used between researcher and responders. Age, sex, address, educational status, family history, age of disease diagnosis, commencement of treatment, and number of transfusions rated as none, occasional (1-5 times/year), low (6-12 times/year), and high (13-22 times/year) were all included in the study. The results of the echocardiography were then documented.

SPSS version 23.0 was used for data handling. Statistical analysis was expressed as frequencies and percentages for qualitative variables gender, family history of thalassemia, Left ventricular dysfunction, isolated systolic & diastolic dysfunction and global dysfunction. Mean and standard deviation of patient's age, number of transfusions, and age at diagnosis were measured, Effect modifiers age, gender, age at diagnosis, family history of thalassemia were controlled through stratification chi square test was applied. P-value less than 0.05 was kept significant.

Results

A total of 236 patients were included in the study. In table 1 descriptive statistics of all quantitative variables was calculated in term of mean and standard deviation. Mean age of the patients was 10.60±4.064 (5-18) years. Mean number of transfusion was 12.6±4.7 (2-26). Mean age at diagnosis of thalassemia was 4.3±1.8 (3-7) years. In table 2, 110(49.1%) study subjects were female and 126(50.8%) were male patients. While 75(31.78%) study subjects have family history of thalassemia.

UNDER PEER REVIEW

In table 3 echocardiographic finding of cardiomyopathy were stated, 87(36.9%) study subjects have left ventricular dysfunction, 13(14.9%) have global dysfunction, 11(12.6%) have isolated systolic dysfunction and 63(72.4%) have isolated diastolic dysfunction. All patients had dilated cardiomyopathy. In table 4 - 7 stratification for echocardiographic finding were stated with respect to age, gender, family history of thalassemia, age at diagnosis and number of blood transfusions. P-values were significant with p-value=<0.05. Mean and standard deviation were used for age and number of transfusions, while frequencies and percentages were used for gender and family history of thalassemia.

Table: 1 Descriptive statistics of study participants (n=236)

Variables	**n**	**Mean**	**Std. Deviation**
Age (Years)	236	10.60	4.064
No. of transfusions	236	12.6	4.7
Age at diagnosis	236	4.3	1.8

Table: 2 Demographic characteristics of study participants (n=236)

Variables	**Frequency(n)**	**Percentages**
Gender		
Female	110	49.20

UNDER PEER REVIEW

Male	126	50.80
Family H/o thalassemia		
Yes	75	31.78
No	161	68.22

Table: 3 Distribution of echocardiographic findings (n=236)

Cardiomyopathy (Echocardiographic finding)	**Frequency**	**Percentages**
Left ventricular dysfunction	**87**	**36.8**
Global dysfunction	13	14.9
Isolates systolic dysfunction	11	12.6
Isolated diastolic dysfunction	63	72.4

Table: 4 Stratification of left ventricular dysfunction with respect to effect modifiers (n=236)

Effect modifiers	**Left ventricular**	**Total**	**P-**

UNDER PEER REVIEW

	dysfunction			**value**
	Yes	**No**		
Age				
<10 years	38(33.3%)	76(66.7%)	114(100%)	
≥10 years	49(39.8%)	74(60.2%)	122(100%)	0.23
Gender				
Female	41(37.3%)	69(62.7%)	110(100%)	
Male	46(36.5%)	80(63.5%)	126(100%)	0.90
Family H/o thalassemia				0.29
Yes	24(32%)	51(68%)	75(100%)	
No	63(39.1%)	98(60.9%)	161(100%)	
No. of transfusions				
<10	29(30.9%)	65(69.1%)	94(100%)	0.12
≥10	58(40.8%)	84(59.2%)	142(100%)	
Age at diagnosis				0.03
<5 years	51(32.3%)	107(67.7%)	158(100%)	

UNDER PEER REVIEW

≥5 years	36(46.2%)	42(53.8%)	78(100%)	

Table: 5 Stratification of Isolated systolic dysfunction with respect to effect modifiers (n=236)

Effect modifiers	**Isolated systolic dysfunction**		**Total**	**P-value**
	Yes	**No**		
Age				0.8
<10 years	5(4.4%)	109(95.6%)	114(100%)	
≥10 years	6(4.9%)	116(95.1%)	122(100%)	
Gender				0.5
Female	4(3.6%)	106(96.4%)	110(100%)	
Male	7(5.6%)	119(94.4%)	126(100%)	
Family H/o thalassemia				0.02
Yes	7(9.3%)	68(90.7%)	75(100%)	
No	4(2.5%)	157(97.5%)	161(100%)	

UNDER PEER REVIEW

No. of transfusions				
<10	4(4.3%)	90(95.7%)	94(100%)	0.8
≥10	7(4.9%)	135(95.1%)	142(100%)	
Age at diagnosis				
<5 years	5(3.2%)	153(96.8%)	158(100%)	0.12
≥5 years	6(7.7%)	72(92.3%)	78(100%)	

UNDER PEER REVIEW

Table: 6

Stratification of Isolated diastolic dysfunction with respect to effect modifiers (n=236)

Effect modifiers	Isolated diastolic dysfunction		Total	P-value
	Yes	No		
Age				
<10 years	41(36%)	73(64%)	114(100%)	
≥10 years	32(26.2%)	90(73.8%)	122(100%)	0.16
Gender				
Female	31(28.2%)	79(71.8%)	110(100%)	
Male	42(33.3%)	84(66.7%)	126(100%)	0.39
Family H/o thalassemia				0.39
Yes	26(34.7%)	49(65.3%)	75(100%)	
No	47(29.2%)	114(70.8%)	161(100%)	
No. of transfusions				
<10	33(35.1%)	61(64.9%)	94(100%)	0.25
≥10	40(28.2%)	102(71.8%)	142(100%)	
Age at diagnosis				0.24

UNDER PEER REVIEW

<5 years	45(28.5%)	113(71.5%)	158(100%)	
≥5 years	28(35.9%)	50(64.1%)	78(100%)	

Table: 7 Stratification of global dysfunction with respect to effect modifiers (n=236)

Effect modifiers	**Global dysfunction**		**Total**	**P-value**
	Yes	**No**		
Age				
<10 years	4(3.5%)	110(96.5%)	114(100%)	
≥10 years	9(7.4%)	113(92.6%)	122(100%)	0.19
Gender				
Female	5(4.5%)	105(95.5%)	110(100%)	
Male	8(6.3%)	118(93.7%)	126(100%)	0.54
Family H/o thalassemia				
Yes	6(8%)	69(92%)	75(100%)	0.25
No	7(4.3%)	154(95.7%)	161(100%)	
No. of transfusions				0.25

UNDER PEER REVIEW

<10	3(3.2%)	91(96.8%)	94(100%)	
≥10	10(7%)	132(93%)	142(100%)	
Age at diagnosis				
<5 years	5(3.2%)	153(96.8%)	158(100%)	0.02
≥5 years	8(10.3%)	70(89.7%)	78(100%)	

Discussion

Higher LV early diastolic filling and a high E/A ratio in this case study indicated a restricted diastolic pattern and, as a result, a stiff LV wall. Yaprak et al. [10] found that -TM patients (n = 63) exhibited significantly larger E wave, E/A ratio, and lower A wave velocity, indicating restrictive pattern in 54 percent of the study group. In a similar study, Doppler measurements of trans-mitral diastolic filling in individuals with -TM (n = 32, none of whom had heart failure) revealed a restrictive pattern. [11] This was also in line with a prior analysis that stated that the most common finding in individuals with TM is a high E/A ratio [12].

UNDER PEER REVIEW

The TDI peak systolic velocity (Sm) and diastolic parameter (E/Em ratio) in our instance were both abnormally high. Marci et al. found a link between baseline systolic velocity (Sm) of less than 7.9 cm/s and cardiac problems (P 0.05). They also discovered that systolic velocity is inversely associated to plasmatic levels of NT-proBNP (P 0.001) [13].

The current study found that 40 women vs 19 males had normal LV systolic function, with a significant difference (P=0.024), despite the fact that both groups received the same treatment. These results are comparable to those reported by Hahallis et al [14]. For example, Bosi et al. [15] found that serum ferritin levels >2,500 ng/mL were associated with lower LV systolic performance than levels 1,000 ng/mL. When serum ferritin levels were less than 2,500 ng/mL, Silvilairat et al. [16] discovered that cardiac systolic function was normal. Shahmohammadi et al. [17], Finazzo et al. [18], and Yapark et al. [19] conducted research that were similar to ours. The disparity across the studies could be due to differing time intervals between the onset of cardiac siderosis and the onset of cardiac dysfunction.

Previous research compared thalassemia major patients' cardiac function to that of a healthy control group, ignoring the separate effects of anaemia on the heart. This is the only study that we are aware of that compares thalassemia major patients to groups of healthy controls or anaemic patients. Anemia has been linked to changes in cardiovascular structure and function.

In comparison to healthy controls, people with thalassemia major had decreased haemoglobin levels at the time of the echocardiographic exam (at least 4 hours following blood transfusion). Patients with thalassemia major had higher haemoglobin levels than those with anaemia.

We also found that the amount of thalassemia major haemoglobin before blood transfusion on the day of echocardiographic evaluation did not differ substantially from the Anemia group (data not shown). As a result, we may conclude from our research that the cardiac changes observed in the Thalassemia group versus the Anemia group are due to iron overload rather than anaemia. A large observational research of 6,657 people found that a left atrium volume/body surface area ratio of > 34 ml/m2 is an independent risk factor for heart failure [20].

UNDER PEER REVIEW

Limitations

Our study has some limitations, such as the small number of participants and the lack tissue Doppler that can detect left ventricular diastolic abnormalities more better.

Conclusion: Heart disease is the primary determinant of prognosis and survival in β-thalassemia. In this study we found a significant number of thalassemia children having cardiac involvement and ventricular dysfunction

Ethical Approval:

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

Consent

As per international standard or university standard, patients' written consent has been collected and preserved by the author(s).

References

1. Thiyagarajan A, Bhattacharya S, Sharma N, Srivastava A, Dhar DK. Need for a universal thalassemia screening programme in India? A public health perspective. Journal of Family Medicine and Primary Care. 2019; 8(5):1528.
2. Sharma DC, Arya A, Kishor P, Woike P, Bindal J. Overview on thalassemias: a review article. Medico Research Chronicles. 2017; 4(03):325-37.
3. Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB. Carrier screening for beta-thalassaemia: a review of international practice. European journal of human genetics. 2010; 18(10):1077-83.

UNDER PEER REVIEW

4. Ahmed, M., Sharif, M.S., Yaqoob, R., Nadeem, M.S.A., Haroon, Z. and Iqbal, T., 2019. Impact of Thalassemia Centre on awareness of parents of Thalassemic patients about the disease: Comparative study in Muzaffarabad and Kotli districts of Azad Kashmir. Pakistan Journal of Physiology, 15(2), pp.11-15.
5. Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras D, Keren A. β-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circulation: Heart Failure. 2010; 3(3):451-8.
6. Neufeld EJ. Oral chelators' deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006; 107(9):3436-41.
7. Rammos A, Meladinis V, Vovas G, Patsouras D. Restrictive cardiomyopathies: the importance of noninvasive cardiac imaging modalities in diagnosis and treatment—a systematic review. Radiology research and practice. 2017; 2017.
8. Koplan BA, Stevenson WG. Ventricular tachycardia and sudden cardiac death. InMayo clinic proceedings 2009 Mar 1 (Vol. 84, No. 3, pp. 289-297). Elsevier.
9. Arshad MS, Hyder SN. Evidence of abnormal left ventricular function in patients with thalassemia major: an echocardiography based study. Journal of Ayub Medical College Abbottabad. 2009; 21(2):37-41.
10. Yaprak (Hızarcıoğlu) Karavana S, Güneri P, Ertan G. Benzydamine hydrochloride buccal bioadhesive gels designed for oral ulcers: preparation, rheological, textural, mucoadhesive and release properties. Pharmaceutical development and technology. 2009; 14(6):623-31.

UNDER PEER REVIEW

11. Deraz SE, Abd El Naby SA, Mahmoud AA. Assessment of ventricular dysfunction in Egyptian children with Beta-thalassemia major. Hematology/Oncology and Stem Cell Therapy. 2021; 14(3):206-13.
12. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, Karagiorga M. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005; 127(5):1523-30.
13. Marcí M, Pitrolo L, Lo Pinto C, Sanfilippo N, Malizia R. Detection of early cardiac dysfunction in patients with Beta thalassemia by tissue Doppler echocardiography. Echocardiography. 2011; 28(2):175-80.
14. Moussavi F, Ghasabeh MA, Roodpeyma S, Alavi S, Shakiba M, Gheiratmand R, Omidghaemi M. Optimal method for early detection of cardiac disorders in thalassemia major patients: magnetic resonance imaging or echocardiography?. Blood research. 2014; 49(3):182-6.
15. Moussavi F, Ghasabeh MA, Roodpeyma S, Alavi S, Shakiba M, Gheiratmand R, Omidghaemi M. Optimal method for early detection of cardiac disorders in thalassemia major patients: magnetic resonance imaging or echocardiography?. Blood research. 2014; 49(3):182-6.
16. Silvilairat S, Charoenkwan P, Saekho S, Tantiworawit A, Phrommintikul A, Srichairatanakool S, Chattipakorn N. Heart rate variability for early detection of cardiac iron deposition in patients with transfusion-dependent thalassemia. PloS one. 2016; 11(10):e0164300.
17. SHAH, MOHAMMADI AA, P. N. Davari, MOGHADAM MY AARABI, M. Meraji, A. TABIBI, and H. Mortezaeian. "Echocardiographic assessment of cardiac involvement in

UNDER PEER REVIEW

patients with thalassemia major: evidence of abnormal relaxation pattern of the left ventricle in children and young patients." (2006): 31-36.

18. Midiri M, Finazzo M, Brancato M, Hoffmann E, Indovina G, Maria MD, Lagalla R. Arrhythmogenic right ventricular dysplasia: MR features. European radiology. 1997;7(3):307-12.
19. Helvaci MR, Yaprak M, Abyad A, Pocock L. Atherosclerotic background of hepatosteatosis in sickle cell diseases. World Family Med. 2018; 16(3):12-8.
20. Gupta S, Matulevicius SA, Ayers CR, Berry JD, Patel PC, Markham DW, Levine BD, Chin KM, De Lemos JA, Peshock RM, Drazner MH. Left atrial structure and function and clinical outcomes in the general population. European heart journal. 2013; 34(4):278-85.

UNDER PEER REVIEW